{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:14:34Z","timestamp":1760919274409,"version":"build-2065373602"},"reference-count":83,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cld.2025.06.003","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T03:59:32Z","timestamp":1753156772000},"page":"657-672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Status and Future Directions in the Pharmacologic Management of Cirrhosis"],"prefix":"10.1016","volume":"29","author":[{"given":"Chalermrat","family":"Bunchorntavakul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cld.2025.06.003_bib1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.06.003_bib2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/HEP.0000000000000460","article-title":"Etiological cure prevents further decompensation and mortality in patients with cirrhosis with ascites as the single first decompensating event","volume":"78","author":"Tonon","year":"2023","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2025.06.003_bib3","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","article-title":"Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection","volume":"154","author":"El-Sherif","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2025.06.003_bib4","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jhep.2022.07.037","article-title":"Validation of baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis","volume":"77","author":"Wang","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.06.003_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2021.02.033","article-title":"A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement","volume":"75","author":"Pose","year":"2021","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.06.003_bib6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cld.2019.06.004","article-title":"Pharmacologic management of portal hypertension","volume":"23","author":"Bunchorntavakul","year":"2019","journal-title":"Clin Liver Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2025.06.003_bib7","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jhep.2021.01.024","article-title":"The search for disease-modifying agents in decompensated cirrhosis: from drug repurposing to drug discovery","volume":"75","author":"Caraceni","year":"2021","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.06.003_bib8","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/gutjnl-2023-330584","article-title":"Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers","volume":"73","author":"Trebicka","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.cld.2025.06.003_bib9","article-title":"Beta-blockers in patients with liver cirrhosis: pragmatism or perfection?","volume":"9","author":"Sauerbruch","year":"2022","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.cld.2025.06.003_bib10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","article-title":"Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis","volume":"58","author":"Reiberger","year":"2013","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.06.003_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010902","article-title":"Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis","volume":"6","author":"Li","year":"2016","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.cld.2025.06.003_bib12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/apt.12634","article-title":"Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis","volume":"39","author":"Sinagra","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"10181","key":"10.1016\/j.cld.2025.06.003_bib13","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cld.2025.06.003_bib14","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jhep.2022.05.021","article-title":"Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis","volume":"77","author":"Villanueva","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.06.003_bib15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/hep.32737","article-title":"Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: a national cohort study","volume":"77","author":"Serper","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2025.06.003_bib16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cgh.2024.08.012","article-title":"Beta-blockers lower first decompensation in patients with cirrhosis and enduring portal hypertension after etiological treatment","volume":"23","author":"Turco","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.06.003_bib17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2024.09.014","article-title":"Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: a post hoc analysis of the PREDESCI trial","volume":"82","author":"Dajti","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.06.003_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13063-024-08063-3","article-title":"Beta-blockers or placebo for primary prophylaxis (BOPPP) of oesophageal varices: study protocol for a randomised controlled trial","volume":"25","author":"Patel","year":"2024","journal-title":"Trials"},{"issue":"7","key":"10.1016\/j.cld.2025.06.003_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-081623","article-title":"Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China","volume":"14","author":"Liu","year":"2024","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.cld.2025.06.003_bib20","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jhep.2022.03.005","article-title":"Long-term albumin treatment in patients with cirrhosis and ascites","volume":"76","author":"Caraceni","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.06.003_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2019.03.021","article-title":"Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis","volume":"157","author":"Fernandez","year":"2019","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cld.2025.06.003_bib22","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa2022166","article-title":"A randomized trial of albumin infusions in hospitalized patients with cirrhosis","volume":"384","author":"China","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cld.2025.06.003_bib23","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2018.08.006","article-title":"Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial","volume":"69","author":"Sola","year":"2018","journal-title":"J Hepatol"},{"issue":"10138","key":"10.1016\/j.cld.2025.06.003_bib24","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2025.06.003_bib25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.gastro.2023.10.016","article-title":"AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: expert review","volume":"166","author":"Garcia-Tsao","year":"2024","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2025.06.003_bib26","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jhep.2020.08.021","article-title":"On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites","volume":"74","author":"Caraceni","year":"2021","journal-title":"J Hepatol"},{"journal-title":"Grifols Press Release","article-title":"Grifols announces topline phase 3 data on long-term albutein\u00ae (albumin [Human] U.S.P.) therapy for decompensated cirrhosis with ascites","year":"2024","key":"10.1016\/j.cld.2025.06.003_bib27"},{"issue":"1","key":"10.1016\/j.cld.2025.06.003_bib28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: old drugs as new therapy for liver diseases?","volume":"70","author":"Pose","year":"2019","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.06.003_bib29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis","volume":"126","author":"Zafra","year":"2004","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2025.06.003_bib30","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.cld.2025.06.003_bib31","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of Simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2025.06.003_bib32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.06.003_bib33","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.06.003_bib34","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"issue":"10059","key":"10.1016\/j.cld.2025.06.003_bib35","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2025.06.003_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.06.003_bib37","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jama.2024.27441","article-title":"Simvastatin and rifaximin in decompensated cirrhosis: a randomized clinical trial","volume":"333","author":"Pose","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2025.06.003_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106367","article-title":"SACRED: effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: statins and cirrhosis: reducing events of decompensation","volume":"104","author":"Kaplan","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"10.1016\/j.cld.2025.06.003_bib39","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0016-5085(00)70368-4","article-title":"Angiotensin II induces contraction and proliferation of human hepatic stellate cells","volume":"118","author":"Bataller","year":"2000","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2025.06.003_bib40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jhep.2010.03.013","article-title":"Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis","volume":"53","author":"Tandon","year":"2010","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.06.003_bib41","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11845-018-1765-6","article-title":"Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials","volume":"187","author":"Yao","year":"2018","journal-title":"Ir J Med Sci"},{"issue":"4","key":"10.1016\/j.cld.2025.06.003_bib42","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3350\/cmh.2014.20.4.376","article-title":"Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension","volume":"20","author":"Kim","year":"2014","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.06.003_bib43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/hep.32294","article-title":"Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease","volume":"76","author":"Zhang","year":"2022","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2025.06.003_bib44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cgh.2023.07.009","article-title":"Association of renin-angiotensin system inhibition with liver-related events and mortality in compensated cirrhosis","volume":"22","author":"Elhence","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.06.003_bib45","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.14309\/ajg.0000000000002976","article-title":"The association between angiotensin-converting enzyme inhibitor or angiotensin receptor blocker exposure and key cirrhosis-related outcomes","volume":"120","author":"Wang","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2025.06.003_bib46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/cld.714","article-title":"SGLT2 inhibitors and cirrhosis: a unique perspective on the comanagement of diabetes mellitus and ascites","volume":"11","author":"Saffo","year":"2018","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"6","key":"10.1016\/j.cld.2025.06.003_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12062253","article-title":"The effects of SGLT2 inhibitors on liver cirrhosis patients with refractory ascites: a literature review","volume":"12","author":"Miyamoto","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.cld.2025.06.003_bib48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3350\/cmh.2016.0110","article-title":"Anticoagulation in cirrhosis: a new paradigm?","volume":"23","author":"Leonardi","year":"2017","journal-title":"Clin Mol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2025.06.003_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cells7080085","article-title":"Coagulation, microenvironment and liver fibrosis","volume":"7","author":"Bitto","year":"2018","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.cld.2025.06.003_bib50","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis","volume":"153","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2025.06.003_bib51","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.gastro.2024.10.038","article-title":"AGA clinical practice update on management of portal vein thrombosis in patients with cirrhosis: expert review","volume":"168","author":"Davis","year":"2024","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2025.06.003_bib52","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.dld.2021.07.039","article-title":"Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: a systematic review and meta-analysis","volume":"54","author":"Koh","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2025.06.003_bib53","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/apt.18474","article-title":"Experience with dabigatran on rate of portal vein thrombosis recanalization, disease progression and survival","volume":"61","author":"Premkumar","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2025.06.003_bib54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cld.2016.08.009","article-title":"Drug hepatotoxicity: newer agents","volume":"21","author":"Bunchorntavakul","year":"2017","journal-title":"Clin Liver Dis"},{"issue":"5","key":"10.1016\/j.cld.2025.06.003_bib55","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2025.06.003_bib56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2023.02.023","article-title":"Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis","volume":"79","author":"Guerrero","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.06.003_bib57","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.jhep.2023.03.022","article-title":"Anticoagulation to prevent disease progression in patients with cirrhosis","volume":"79","author":"Lisman","year":"2023","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2025.06.003_bib58","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S2468-1253(24)00078-5","article-title":"Infections in cirrhosis","volume":"9","author":"Piano","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.06.003_bib59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41575-020-00376-3","article-title":"Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure","volume":"18","author":"Trebicka","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.06.003_bib60","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1053\/j.gastro.2007.06.065","article-title":"Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis","volume":"133","author":"Fernandez","year":"2007","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2025.06.003_bib61","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1053\/j.gastro.2018.08.026","article-title":"Effects of long-term norfloxacin therapy in patients with advanced cirrhosis","volume":"155","author":"Moreau","year":"2018","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2025.06.003_bib62","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000003075","article-title":"Higher rate of spontaneous bacterial peritonitis recurrence with secondary spontaneous bacterial peritonitis prophylaxis compared with No prophylaxis in 2 national cirrhosis cohorts","volume":"120","author":"Silvey","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2025.06.003_bib63","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/hep.31708","article-title":"The use of rifaximin in patients with cirrhosis","volume":"74","author":"Caraceni","year":"2021","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2025.06.003_bib64","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/MEG.0000000000000940","article-title":"Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis","volume":"29","author":"Kamal","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.06.003_bib65","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.28898","article-title":"Rifaximin has no effect on hemodynamics in decompensated cirrhosis: a randomized, double-blind, placebo-controlled trial","volume":"65","author":"Kimer","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2025.06.003_bib66","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.30690","article-title":"Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial","volume":"70","author":"Bajaj","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2025.06.003_bib67","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1053\/j.gastro.2019.01.033","article-title":"Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis","volume":"156","author":"Bajaj","year":"2019","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cld.2025.06.003_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102207","article-title":"Granulocyte colony stimulating factor in decompensated cirrhosis, acute alcoholic hepatitis, and acute-on-chronic liver failure: a comprehensive meta-analysis of randomized controlled trials","volume":"47","author":"Di Martino","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2025.06.003_bib69","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/hep.29763","article-title":"Outcomes after multiple courses of granulocyte colony-stimulating factor and growth hormone in decompensated cirrhosis: a randomized trial","volume":"68","author":"Verma","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2025.06.003_bib70","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MEG.0000000000000801","article-title":"Granulocyte colony-stimulating factor improves survival of patients with decompensated cirrhosis: a randomized-controlled trial","volume":"29","author":"Prajapati","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2025.06.003_bib71","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1053\/j.gastro.2015.02.054","article-title":"Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis","volume":"148","author":"Kedarisetty","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2025.06.003_bib72","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cgh.2020.02.022","article-title":"Multiple cycles of granulocyte colony-stimulating factor increase survival times of patients with decompensated cirrhosis in a randomized trial","volume":"19","author":"De","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.06.003_bib73","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2468-1253(17)30326-6","article-title":"Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial","volume":"3","author":"Newsome","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.06.003_bib74","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jceh.2019.05.003","article-title":"Granulocyte colony-stimulating factor use in decompensated cirrhosis: lack of survival benefit","volume":"10","author":"Philips","year":"2020","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.06.003_bib75","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jhep.2021.07.033","article-title":"Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: a multicenter randomized trial (GRAFT study)","volume":"75","author":"Engelmann","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2025.06.003_bib76","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s12072-022-10314-x","article-title":"Multiple cycles of granulocyte colony-stimulating factor in decompensated cirrhosis: a double-blind RCT","volume":"16","author":"Venkitaraman","year":"2022","journal-title":"Hepatol Int"},{"issue":"6","key":"10.1016\/j.cld.2025.06.003_bib77","article-title":"Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease","volume":"6","author":"Colli","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.cld.2025.06.003_bib78","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S2468-1253(23)00438-7","article-title":"Pathophysiology and therapeutic options for cirrhotic portal hypertension","volume":"9","author":"Guixe-Muntet","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.003_bib79","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001117","article-title":"Drug treatments to prevent first decompensation in cirrhosis","author":"Kezer","year":"2024","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2025.06.003_bib80","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/lt.25934","article-title":"Multicenter, double-blind, randomized trial of emricasan in hepatitis C-Treated liver transplant recipients with residual fibrosis or cirrhosis","volume":"27","author":"Weinberg","year":"2021","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.cld.2025.06.003_bib81","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","article-title":"Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension","volume":"72","author":"Garcia-Tsao","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.06.003_bib82","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.06.003_bib83","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:25:39Z","timestamp":1760855139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1089326125000431"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.06.003","relation":{},"ISSN":["1089-3261"],"issn-type":[{"type":"print","value":"1089-3261"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Status and Future Directions in the Pharmacologic Management of Cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}